2025
Cost-effectiveness analysis of alternative infant and neonatal rotavirus vaccination schedules in Malawi
Wenger C, Asare E, Kwon J, Li X, Mwinjiwa E, Chinkhumba J, Jere K, Hungerford D, Cunliffe N, Paltiel A, Pitzer V. Cost-effectiveness analysis of alternative infant and neonatal rotavirus vaccination schedules in Malawi. PLOS Global Public Health 2025, 5: e0004341. PMID: 40209158, PMCID: PMC11984971, DOI: 10.1371/journal.pgph.0004341.Peer-Reviewed Original ResearchDose of RotarixNeonatal vaccinationThird doseDisability-adjusted life yearsRotavirus vaccination strategiesVaccination strategiesVaccination scheduleRV3-BB vaccineRotavirus vaccine scheduleModerate-to-severeCurrent rotavirus vaccinesProbabilistic sensitivity analysesRV3-BBPrevent rotavirusRotavirus casesRotavirus vaccineWTP thresholdAlternate infantsVaccine impactSevere diarrheaWeeks of ageRotarixVaccine effectivenessCost-effectiveness analysisCost-effective
2023
Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study
Phillips M, Antillon M, Bilcke J, Bar-Zeev N, Limani F, Debellut F, Pecenka C, Neuzil K, Gordon M, Thindwa D, Paltiel A, Yaesoubi R, Pitzer V. Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study. BMC Infectious Diseases 2023, 23: 143. PMID: 36890448, PMCID: PMC9993384, DOI: 10.1186/s12879-023-08105-2.Peer-Reviewed Original ResearchConceptsTyphoid Conjugate VaccineRoutine vaccinationReactive vaccinationVaccination strategiesOutbreak settingsMultidrug-resistant Salmonella typhiQueen Elizabeth Central HospitalTyphoid fever epidemicYears of ageMonths of ageCost-effectiveness analysisWorld Health OrganizationConjugate vaccineCentral HospitalRoutine immunizationVaccine deploymentPreventive vaccinationVaccinationTyphoid feverCost-effective strategyAge 15Health OrganizationFever epidemicAntimicrobial resistanceOutbreak definitions
2016
Optimal frequency of rabies vaccination campaigns in Sub-Saharan Africa
Bilinski AM, Fitzpatrick MC, Rupprecht CE, Paltiel AD, Galvani AP. Optimal frequency of rabies vaccination campaigns in Sub-Saharan Africa. Proceedings Of The Royal Society B 2016, 283: 20161211. PMID: 27852799, PMCID: PMC5124087, DOI: 10.1098/rspb.2016.1211.Peer-Reviewed Original ResearchConceptsVaccination campaignRabies vaccination campaignsOptimal vaccination strategyPublic health benefitsWorld Health OrganizationVaccination strategiesRabies vaccinationVirus transmission modelDisease reintroductionSub-Saharan AfricaHealth OrganizationHealth benefitsRabies reintroductionRabiesNorthwest TanzaniaHuman deathsPrevious studiesVaccinationYearsDisease
2014
A Marginal Benefit Approach for Vaccinating Influenza “Superspreaders”
Skene KJ, Paltiel AD, Shim E, Galvani AP. A Marginal Benefit Approach for Vaccinating Influenza “Superspreaders”. Medical Decision Making 2014, 34: 536-549. PMID: 24740238, PMCID: PMC4209160, DOI: 10.1177/0272989x14523502.Peer-Reviewed Original ResearchConceptsHerd immunity thresholdSeasonal influenza epidemicsVaccination coverageSeasonal influenzaVaccination strategiesEpidemiological findingsImmunity thresholdHerd immunityInfluenza epidemicsVaccination changesPotential superspreadersSimplified transmission modelVaccinationTarget populationIntervention designEpidemicInfluenzaInterventionTransmission model
2011
The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: Examining the RV144 trial results
Andersson KM, Paltiel AD, Owens DK. The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: Examining the RV144 trial results. Vaccine 2011, 29: 6107-6112. PMID: 21736912, PMCID: PMC3164284, DOI: 10.1016/j.vaccine.2011.06.076.Peer-Reviewed Original ResearchConceptsBooster vaccinationHIV prevalencePopulation coverage levelsRV144 trialHIV vaccineCondom useContinuous vaccinationHIV vaccine regimenPopulation HIV prevalenceDuration of protectionCoverage levelsRV144 vaccineVaccine regimenHIV infectionHeterosexual transmissionModest efficacyVaccine efficacyUnvaccinated populationVaccination strategiesPartial efficacyEfficacy vaccineLower riskVaccinationBooster strategyVaccine
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply